AbbVie Inc (ABBV) : Shelton Capital Management reduced its stake in AbbVie Inc by 14.41% during the most recent quarter end. The investment management company now holds a total of 151,705 shares of AbbVie Inc which is valued at $9.4 Million after selling 25,543 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.AbbVie Inc makes up approximately 0.89% of Shelton Capital Management’s portfolio.
Other Hedge Funds, Including , Altfest L J Co Inc reduced its stake in ABBV by selling 352 shares or 2.97% in the most recent quarter. The Hedge Fund company now holds 11,500 shares of ABBV which is valued at $713,000. AbbVie Inc makes up approx 0.74% of Altfest L J Co Inc’s portfolio.Ridgeworth Capital Management boosted its stake in ABBV in the latest quarter, The investment management firm added 707 additional shares and now holds a total of 3,832 shares of AbbVie Inc which is valued at $237,584.Fernwood Investment Management boosted its stake in ABBV in the latest quarter, The investment management firm added 2,400 additional shares and now holds a total of 16,755 shares of AbbVie Inc which is valued at $1 Million. AbbVie Inc makes up approx 1.05% of Fernwood Investment Management’s portfolio.Gamco Investors Et Al reduced its stake in ABBV by selling 5,140 shares or 12.66% in the most recent quarter. The Hedge Fund company now holds 35,460 shares of ABBV which is valued at $2.2 Million. AbbVie Inc makes up approx 0.01% of Gamco Investors Et Al’s portfolio.Washington Trust Co boosted its stake in ABBV in the latest quarter, The investment management firm added 4,607 additional shares and now holds a total of 134,273 shares of AbbVie Inc which is valued at $8.4 Million. AbbVie Inc makes up approx 0.56% of Washington Trust Co’s portfolio.
AbbVie Inc opened for trading at $61.08 and hit $61.47 on the upside on Wednesday, eventually ending the session at $61.22, with a gain of 0.86% or 0.52 points. The heightened volatility saw the trading volume jump to 58,57,619 shares. Company has a market cap of $99,015 M.
On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.